Table 3.
Association between urinary porphyrine concentrsations and the study variables (age, sex, alcohol, smoking, years of residence, and organochlorintaed compounds in serum).
| TP | Copro I | Copro III | Uro I + UroIII | |||
| Median (25%–75%) | Detectables n (%) | Median (25%-75%) † | Detectables n (%) | Median (25%-75%) † | Detectables n (%) | |
| Age | ||||||
| <45 | 117 (73–185) | 70 (79) | 7 (3–15) | 85 (96) | 29 (11–46) | 31 (35) |
| 45–64 | 89 (62–132) | 62 (74) | 4 (0.5–8) | 67 (80) | 14 (4.5–27.5) | 24 (29) |
| >64 | 83 (56–126)* | 51 (75) | 4 (1.3–9)* | 56 (82)* | 12.5 (3–30)* | 27 (40) |
| Sex | ||||||
| Female | 85 (62–112) | 42 (69) | 5 (0.5–11) | 60 (98) | 20 (10–31) | 17 (28) |
| Male | 107 (65–165)* | 141 (78) | 5 (2–11) | 148 (82)* | 19 (5–37) | 65 (36) |
| Alcohol | ||||||
| No | 99 (62–144) | 52 (71) | 5 (0.5–11) | 67 (92) | 18 (6–35) | 23 (32) |
| Ocasional | 86 (64–143) | 45 (74) | 5 (0.5–10) | 52 (85) | 19 (7–35) | 21 (34) |
| Habitual | 103 (66–162) | 86 (80) | 5 (3–12) | 89 (83) | 20 (5–35) | 38 (36) |
| Smoking | ||||||
| Never | 86 (62–124) | 52 (71) | 5 (0.5–10) | 64 (88) | 19 (6–29) | 19 (26) |
| Ocasional + Ex | 92 (60–146) | 65 (70) | 4 (0.5–10) | 76 (82) | 12 (4–35) | 33 (35) |
| < 20 cigs./day | 103 (83–159) | 30 (91) | 6 (4–9) | 28 (85) | 20 (7–39) | 12 (36) |
| ≥ 20 cigs./day | 127 (81–588)* | 36 (86)* | 6.5 (3.5–15) | 40 (95) | 32 (12–46)* | 18 (43) |
| Years living in Flix | ||||||
| ≤ 20 years | 165 (86, 240) | 21 (91) | 7 (3, 19) | 22 (95) | 27 (17,51) | 10 (43) |
| > 20 years | 94 (62, 143)* | 162 (74) | 5 (0.5, 10)* | 186 (85) | 19 (6, 34)* | 72 (33) |
| HCB ng/ml (tertiles) | ||||||
| <16.1 | 129 (81–176) | 60 (77) | 7 (2–15) | 73 (94) | 26 (8–43) | 29 (37) |
| 16.1–29.5 | 82 (55–126) | 62 (75) | 4 (0.5–10) | 70 (84) | 18 (5–31) | 28 (34) |
| >29.5 | 92 (64–130)* | 61 (76) | 5 (2–8.5)* | 65 (81)* | 14 (5–31.5)* | 25 (31) |
| DDE ng/ml (tertiles) | ||||||
| < 3.22 | 124 (74–179) | 62 (78) | 7 (2–15) | 74 (94) | 26 (7–49) | 31 (39) |
| 3.22 – 9.88 | 105 (65–161) | 60 (75) | 4 (0.5–10) | 64 (80) | 20 (4.5–35) | 22 (28) |
| > 9.88 | 82 (57–117)* | 61 (74) | 5 (2–8.5)* | 70 (85) | 12 (5–26)* | 29 (35) |
| PCBs ng/ml (tertiles) | ||||||
| < 2.08 | 108 (74, 166) | 63 (80) | 6 (2–13) | 72 (91) | 22 (7, 35) | 21 (27) |
| 2.08–4.89 | 99 (61, 172) | 60 (77) | 4 (2–12) | 69 (88) | 20 (6, 38) | 30 (38) |
| > 4.89 | 87 (59, 130)* | 60 (73) | 4.5 (0.5–9) | 67 (80)* | 13.5 (4, 30)* | 31 (37) |
| CB-138 (tertiles) | ||||||
| < 0.55 | 108 (73–116) | 63 (79) | 5.5 (2.5–13) | 73 (91) | 20 (7.5–36.5) | 19 (24) |
| 0.55 – 1.29 | 99 (61–146) | 63 (80) | 5 (2–12) | 69 (87) | 21 (6–38) | 36 (46) |
| > 1.29 | 89 (60–130)* | 57 (70) | 4 (0.5–9) | 66 (80)* | 13 (4–29)* | 27 (33) |
| CB-153 (tertiles) | ||||||
| < 0.61 | 109 (73–161) | 65 (81) | 6 (3–13.5) | 74 (93) | 21 (8.5–35) | 21 (26) |
| 0.61 – 1.36 | 98 (61–173) | 58 (73) | 4 (0.5–11) | 66 (84) | 20 (5–39) | 30 (38) |
| > 1.36 | 87 (61–130) | 60 (73) | 4 (0.5–9)* | 68 (83) | 13 (5–32) | 31 (38) |
| CB-180 (tertiles) | ||||||
| < 0.61 | 110 (73–168) | 64 (80) | 5 (2–11.5) | 72 (90) | 21 (7–38.5) | 22 (28) |
| 0.61 – 1.80 | 94 (61–143) | 59 (75) | 5 (0.5–12) | 73 (92) | 20 (6–37) | 26 (33) |
| > 1.80 | 90 (60–141)* | 60 (73) | 4.5 (0.5–10) | 63 (77)* | 14 (3–29)* | 34 (41) |
TP: total porphyrins; CPI, CPIII: coproporphyrins I, III; UPI, UPIII: uroporphyrins I, III. * p < 0.05 using the extension of the non-parametric Wilcoxon test for linear trend † non-detectable values were set at the median value between 0 and the detectable level